Senseonics has concluded the adult cohort of the ENHANCE pivotal clinical trial of Eversense after the recently completed 365-day visit for the last study subject.

The ENHANCE trial is designed to assess the Eversense system’s safety and accuracy for one year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Eversense systems were inserted into more than 165 adult subjects in four centres in the US.

In September last year, enrollment concluded for the 365-day sensor configuration.

The study data will support the submission of the first 365-day continuous glucose monitoring (CGS) system to the US Food and Drug Administration (FDA).

The data collected during this study was also utilised to support the submission of the integrated continuous glucose monitoring (iCGM) designation to the FDA at the start of this year.

Senseonics chief medical officer Francine Kaufman said: “We are pleased that all patients have completed the testing for the adult arm of the ENHANCE clinical study.

“Demonstration of safe and accurate performance of Eversense for 365 days in this study would further validate its ability to facilitate more effective and longer-term management of diabetes.

“This represents a major milestone for Senseonics as we work towards offering the differentiated benefits of implantable CGM for one full year with just a single sensor.”

The FDA approved an investigational device exemption supplement to expand the study to include paediatric patients aged 14 to 18. The first paediatric participants were enrolled in the second quarter of this year.

The insertion in the first patient was performed at the AMCR Institute in Escondido, California, US, under the guidance of Dr Timothy Bailey – the head of the AMCR Institute.